Aortic plaque regression as determined by magnetic resonance imaging with high-dose and low-dose statin therapy.
Level 2 - randomized trial
Individual randomized controlled trial
PubMed 18545070 · doi:10.2459/JCM.0b013e3282f447c3
What was done
A randomized controlled trial evaluated 31 patients with established moderate-to-severe atherosclerosis assigned to either high-dose (80 mg/day) or low-dose (20 mg/day) simvastatin therapy for 12 months. Changes in aortic vessel wall and lumen areas and volumes were measured by transoesophageal magnetic resonance imaging (TEMRI) at baseline and 12 months.
What was found
High-dose simvastatin resulted in significantly greater reductions compared to low-dose therapy in LDL-c (difference of 10 mg/dl, P = 0.001), total cholesterol (difference of 16.2 mg/dl, P < 0.001), aortic vessel wall area (difference of 19.0 mm2, P < 0.001), and vessel wall volume (difference of 343.4 mm3, P < 0.001). High-dose statin therapy also produced significantly greater increases in lumen area (54.4 mm2, P < 0.001) and lumen volume (1038 mm3, P < 0.001). LDL-c lowering was significantly associated with aortic wall area and volume reduction in both groups.
Why it matters
This study provides direct imaging evidence that high-dose statin therapy achieves greater structural regression of aortic atherosclerotic plaque and lumen enlargement than low-dose therapy over 12 months.
Limits
The sample size was very small (n = 31). The study measured surrogate imaging endpoints rather than hard clinical cardiovascular outcomes, and the abstract provides no information on blinding, adverse events, or long-term clinical durability.
Cited by
- contradicts Low doses of statins are sufficient to impact vascular inflammation, lower CRP, improve endothelial function, and stabilize arterial plaque without needing high or moderate doses.